Company Description
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders.
The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder.
It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women’s health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders.
In addition, the company’s clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines.
It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Shawn Singh |
Contact Details
Address: 343 Allerton Avenue South San Francisco, California 94080 United States | |
| Phone | 650 577 3600 |
| Website | vistagen.com |
Stock Details
| Ticker Symbol | VTGN |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001411685 |
| CUSIP Number | 92840H202 |
| ISIN Number | US92840H4002 |
| Employer ID | 20-5093315 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shawn K. Singh J.D. | Chief Executive Officer and Director |
| Cynthia Lynn Anderson CPA | Vice President and Chief Financial Officer |
| Joshua S. Prince M.B.A. | Chief Operating Officer |
| Reid G. Adler Esq., J.D. | Chief Corporate Development Officer and General Counsel |
| Mark Adrian McPartland | Senior Vice President of Investor Relations |
| Trisha Fitzmaurice | Senior Vice President of Human Resources |
| Dr. Allen Easley Cato III, M.D., Ph.D. | Senior Vice President of Development Operations |
| Dr. Mark J. Ginski Ph.D. | Senior Vice President and Head of Chemistry, Manufacturing and Controls |
| Mark Flather | Senior Vice President of Corporate Strategy and Capital Markets |
| Dr. Erik Berglund M.D., Ph.D. | Senior Vice President of Global Regulatory Affairs and Pharmacovigilance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 28, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Jul 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |